+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Ulcerative Colitis Market By Disease Type, By Molecule Type, By Route of Administration: Global Opportunity Analysis and Industry Forecast, 2020-2030

  • PDF Icon

    Report

  • 225 Pages
  • March 2022
  • Region: Global
  • Allied Market Research
  • ID: 5640557
Description Jump to:
The ulcerative colitis market was valued at $6,180.29 million in 2020, and is estimated to reach $10,764.66 million by 2030, growing at a CAGR of 5.7% from 2021 to 2030. Ulcerative colitis (UC) is an inflammatory gastrointestinal disease that affects the colon or large intestine. UC is characterized as an incurable disease with low mortality rate and is generally diagnosed in adolescence and early adulthood.

Growth of the global UC market is majorly driven by alarming increase in number of chronic inflammatory bowel disease, rise in government initiatives for development of pharmaceutical industry, and increase in number of approvals for UC product. In addition, for instance, in June 2021, Pfizer Inc., initiated a phase III clinical trial to assess the efficacy, safety, and pharmacokinetics of tofacitinib in pediatric patients with moderately to severely active UC. The rise in new product launches drive the growth of the market. Moreover, according to the survey conducted by Marc D Basson on UC, in 2019, about one million people were affected with UC. Furthermore, as per Statista, around 2.5 million people were affected with inflammatory bowel disease in the U.S. Hence, the factors that drive the growth of the market are increase in incidences of inflammatory bowel disease and extensive uses of ulcerative colitis drugs.

Increase in government support for management of UC and surge in demand for effective treatment are the major factors that drive the global UC market. In addition, the key players such as Abbott Laboratories, Astrazeneca Plc., and Elli-Lilly provide numerous treatment products for UC, which contributes toward the market growth.

The cause of inflammatory bowel disease is known to involve an interaction between genes, the immune system, and environmental factors. Thus, increase in frequency of smoking causes the UC, which is expected to contribute towards the growth of UC market.

However, patent expiry and availability of alternative surgery option for UC treatment restrict the market growth. Presently, people are more aware of health, which, in turn, compels them to maintain their health condition and increase demand for treatment of ulcerative colitis drugs. This has encouraged many key players to enter emerging market, thus offering lucrative growth opportunities in the ulcerative colitis market.

The ulcerative colitis market is segmented on the basis of disease type, molecule type, route of administration and region. By type, the market is categorized into mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis.

Depending on molecule type, it is divided into small molecules and biologics. As per route of administration, it is bifurcated into oral and injectable. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global ulcerative colitis market are Abbott Laboratories, Ajinomoto, Astrazeneca Plc., Eli-Lilly, GlaxoSmithKline Plc., Index Pharmaceuticals Holdings AB, Johnson & Johnson, Merck & Co., Pfizer Inc., and Sanofi.

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the ulcerative colitis market analysis from 2020 to 2030 to identify the prevailing ulcerative colitis market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the ulcerative colitis market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global ulcerative colitis market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments


By Disease Type

  • Mild UC
  • Moderate UC
  • Severe UC

By Molecule Type

  • Biologics
  • Small Molecules

By Route of Administration

  • Oral
  • Injectables

By Region

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
  • LAMEA
  • Brazil
  • Saudi Arabia
  • South Africa
  • Rest of LAMEA

Key Market Players

  • ABBOTT LABORATORIES
  • AJINOMOTO CO. INC.
  • ASTRAZENECA PLC
  • ELI-LILLY
  • INDEX PHARMACEUTICALS HOLDINGS AB
  • GLAXOSIMITHKLINE PLC
  • JOHNSON & JOHNSON
  • Merck & Co. Inc.
  • Pfizer Inc.
  • SANOFI S.A

Table of Contents

CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Top player positioning
3.5. Market dynamics
3.5.1. Drivers
3.5.2. Restraints
3.5.3. Opportunities
3.6. COVID-19 Impact Analysis on the market
CHAPTER 4: ULCERATIVE COLITIS MARKET, BY DISEASE TYPE
4.1 Overview
4.1.1 Market size and forecast
4.2 Mild UC
4.2.1 Key market trends, growth factors and opportunities
4.2.2 Market size and forecast, by region
4.2.3 Market analysis by country
4.3 Moderate UC
4.3.1 Key market trends, growth factors and opportunities
4.3.2 Market size and forecast, by region
4.3.3 Market analysis by country
4.4 Severe UC
4.4.1 Key market trends, growth factors and opportunities
4.4.2 Market size and forecast, by region
4.4.3 Market analysis by country
CHAPTER 5: ULCERATIVE COLITIS MARKET, BY MOLECULE TYPE
5.1 Overview
5.1.1 Market size and forecast
5.2 Biologics
5.2.1 Key market trends, growth factors and opportunities
5.2.2 Market size and forecast, by region
5.2.3 Market analysis by country
5.3 Small Molecules
5.3.1 Key market trends, growth factors and opportunities
5.3.2 Market size and forecast, by region
5.3.3 Market analysis by country
CHAPTER 6: ULCERATIVE COLITIS MARKET, BY ROUTE OF ADMINISTRATION
6.1 Overview
6.1.1 Market size and forecast
6.2 Oral
6.2.1 Key market trends, growth factors and opportunities
6.2.2 Market size and forecast, by region
6.2.3 Market analysis by country
6.3 Injectables
6.3.1 Key market trends, growth factors and opportunities
6.3.2 Market size and forecast, by region
6.3.3 Market analysis by country
CHAPTER 7: ULCERATIVE COLITIS MARKET, BY REGION
7.1 Overview
7.1.1 Market size and forecast
7.2 North America
7.2.1 Key trends and opportunities
7.2.2 North America Market size and forecast, by Disease Type
7.2.3 North America Market size and forecast, by Molecule Type
7.2.4 North America Market size and forecast, by Route of Administration
7.2.5 North America Market size and forecast, by country
7.2.5.1 U.S.
7.2.5.1.1 Market size and forecast, by Disease Type
7.2.5.1.2 Market size and forecast, by Molecule Type
7.2.5.1.3 Market size and forecast, by Route of Administration
7.2.5.2 Canada
7.2.5.2.1 Market size and forecast, by Disease Type
7.2.5.2.2 Market size and forecast, by Molecule Type
7.2.5.2.3 Market size and forecast, by Route of Administration
7.2.5.3 Mexico
7.2.5.3.1 Market size and forecast, by Disease Type
7.2.5.3.2 Market size and forecast, by Molecule Type
7.2.5.3.3 Market size and forecast, by Route of Administration
7.3 Europe
7.3.1 Key trends and opportunities
7.3.2 Europe Market size and forecast, by Disease Type
7.3.3 Europe Market size and forecast, by Molecule Type
7.3.4 Europe Market size and forecast, by Route of Administration
7.3.5 Europe Market size and forecast, by country
7.3.5.1 Germany
7.3.5.1.1 Market size and forecast, by Disease Type
7.3.5.1.2 Market size and forecast, by Molecule Type
7.3.5.1.3 Market size and forecast, by Route of Administration
7.3.5.2 France
7.3.5.2.1 Market size and forecast, by Disease Type
7.3.5.2.2 Market size and forecast, by Molecule Type
7.3.5.2.3 Market size and forecast, by Route of Administration
7.3.5.3 U.K.
7.3.5.3.1 Market size and forecast, by Disease Type
7.3.5.3.2 Market size and forecast, by Molecule Type
7.3.5.3.3 Market size and forecast, by Route of Administration
7.3.5.4 Italy
7.3.5.4.1 Market size and forecast, by Disease Type
7.3.5.4.2 Market size and forecast, by Molecule Type
7.3.5.4.3 Market size and forecast, by Route of Administration
7.3.5.5 Spain
7.3.5.5.1 Market size and forecast, by Disease Type
7.3.5.5.2 Market size and forecast, by Molecule Type
7.3.5.5.3 Market size and forecast, by Route of Administration
7.3.5.6 Rest of Europe
7.3.5.6.1 Market size and forecast, by Disease Type
7.3.5.6.2 Market size and forecast, by Molecule Type
7.3.5.6.3 Market size and forecast, by Route of Administration
7.4 Asia-Pacific
7.4.1 Key trends and opportunities
7.4.2 Asia-Pacific Market size and forecast, by Disease Type
7.4.3 Asia-Pacific Market size and forecast, by Molecule Type
7.4.4 Asia-Pacific Market size and forecast, by Route of Administration
7.4.5 Asia-Pacific Market size and forecast, by country
7.4.5.1 Japan
7.4.5.1.1 Market size and forecast, by Disease Type
7.4.5.1.2 Market size and forecast, by Molecule Type
7.4.5.1.3 Market size and forecast, by Route of Administration
7.4.5.2 China
7.4.5.2.1 Market size and forecast, by Disease Type
7.4.5.2.2 Market size and forecast, by Molecule Type
7.4.5.2.3 Market size and forecast, by Route of Administration
7.4.5.3 India
7.4.5.3.1 Market size and forecast, by Disease Type
7.4.5.3.2 Market size and forecast, by Molecule Type
7.4.5.3.3 Market size and forecast, by Route of Administration
7.4.5.4 Australia
7.4.5.4.1 Market size and forecast, by Disease Type
7.4.5.4.2 Market size and forecast, by Molecule Type
7.4.5.4.3 Market size and forecast, by Route of Administration
7.4.5.5 South Korea
7.4.5.5.1 Market size and forecast, by Disease Type
7.4.5.5.2 Market size and forecast, by Molecule Type
7.4.5.5.3 Market size and forecast, by Route of Administration
7.4.5.6 Rest of Asia-Pacific
7.4.5.6.1 Market size and forecast, by Disease Type
7.4.5.6.2 Market size and forecast, by Molecule Type
7.4.5.6.3 Market size and forecast, by Route of Administration
7.5 LAMEA
7.5.1 Key trends and opportunities
7.5.2 LAMEA Market size and forecast, by Disease Type
7.5.3 LAMEA Market size and forecast, by Molecule Type
7.5.4 LAMEA Market size and forecast, by Route of Administration
7.5.5 LAMEA Market size and forecast, by country
7.5.5.1 Brazil
7.5.5.1.1 Market size and forecast, by Disease Type
7.5.5.1.2 Market size and forecast, by Molecule Type
7.5.5.1.3 Market size and forecast, by Route of Administration
7.5.5.2 Saudi Arabia
7.5.5.2.1 Market size and forecast, by Disease Type
7.5.5.2.2 Market size and forecast, by Molecule Type
7.5.5.2.3 Market size and forecast, by Route of Administration
7.5.5.3 South Africa
7.5.5.3.1 Market size and forecast, by Disease Type
7.5.5.3.2 Market size and forecast, by Molecule Type
7.5.5.3.3 Market size and forecast, by Route of Administration
7.5.5.4 Rest of LAMEA
7.5.5.4.1 Market size and forecast, by Disease Type
7.5.5.4.2 Market size and forecast, by Molecule Type
7.5.5.4.3 Market size and forecast, by Route of Administration
CHAPTER 8: COMPANY LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Key developments
CHAPTER 9: COMPANY PROFILES
9.1 ABBOTT LABORATORIES
9.1.1 Company overview
9.1.2 Company snapshot
9.1.3 Operating business segments
9.1.4 Product portfolio
9.1.5 Business performance
9.1.6 Key strategic moves and developments
9.2 AJINOMOTO CO. INC.
9.2.1 Company overview
9.2.2 Company snapshot
9.2.3 Operating business segments
9.2.4 Product portfolio
9.2.5 Business performance
9.2.6 Key strategic moves and developments
9.3 ASTRAZENECA PLC
9.3.1 Company overview
9.3.2 Company snapshot
9.3.3 Operating business segments
9.3.4 Product portfolio
9.3.5 Business performance
9.3.6 Key strategic moves and developments
9.4 ELI-LILLY
9.4.1 Company overview
9.4.2 Company snapshot
9.4.3 Operating business segments
9.4.4 Product portfolio
9.4.5 Business performance
9.4.6 Key strategic moves and developments
9.5 INDEX PHARMACEUTICALS HOLDINGS AB
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Product portfolio
9.5.5 Business performance
9.5.6 Key strategic moves and developments
9.6 GLAXOSIMITHKLINE PLC
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Operating business segments
9.6.4 Product portfolio
9.6.5 Business performance
9.6.6 Key strategic moves and developments
9.7 JOHNSON & JOHNSON
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Product portfolio
9.7.5 Business performance
9.7.6 Key strategic moves and developments
9.8 Merck & Co. Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Product portfolio
9.8.5 Business performance
9.8.6 Key strategic moves and developments
9.9 Pfizer Inc.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Operating business segments
9.9.4 Product portfolio
9.9.5 Business performance
9.9.6 Key strategic moves and developments
9.10 SANOFI S.A
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Operating business segments
9.10.4 Product portfolio
9.10.5 Business performance
9.10.6 Key strategic moves and developments
LIST OF TABLES
Table 1. Global Ulcerative Colitis Market, by Disease Type, 2020-2030, ($Million)
Table 2. Ulcerative Colitis Market Revenue, for Mild Uc, by Region, 2020-2030, ($Million)
Table 3. Ulcerative Colitis Market Mild Uc by Country, 2020-2030, ($Million)
Table 4. Ulcerative Colitis Market Revenue, for Moderate Uc, by Region, 2020-2030, ($Million)
Table 5. Ulcerative Colitis Market Moderate Uc by Country, 2020-2030, ($Million)
Table 6. Ulcerative Colitis Market Revenue, for Severe Uc, by Region, 2020-2030, ($Million)
Table 7. Ulcerative Colitis Market Severe Uc by Country, 2020-2030, ($Million)
Table 8. Global Ulcerative Colitis Market, by Molecule Type, 2020-2030, ($Million)
Table 9. Ulcerative Colitis Market Revenue, for Biologics, by Region, 2020-2030, ($Million)
Table 10. Ulcerative Colitis Market Biologics by Country, 2020-2030, ($Million)
Table 11. Ulcerative Colitis Market Revenue, for Small Molecules, by Region, 2020-2030, ($Million)
Table 12. Ulcerative Colitis Market Small Molecules by Country, 2020-2030, ($Million)
Table 13. Global Ulcerative Colitis Market, by Route of Administration, 2020-2030, ($Million)
Table 14. Ulcerative Colitis Market Revenue, for Oral, by Region, 2020-2030, ($Million)
Table 15. Ulcerative Colitis Market Oral by Country, 2020-2030, ($Million)
Table 16. Ulcerative Colitis Market Revenue, for Injectables, by Region, 2020-2030, ($Million)
Table 17. Ulcerative Colitis Market Injectables by Country, 2020-2030, ($Million)
Table 18. Ulcerative Colitis Market, by Region, 2020-2030, ($Million)
Table 19. North America Ulcerative Colitis Market, by Disease Type, 2020-2030, ($Million)
Table 20. North America Ulcerative Colitis Market, by Molecule Type, 2020-2030, ($Million)
Table 21. North America Ulcerative Colitis Market, by Route of Administration, 2020-2030, ($Million)
Table 22. North America Ulcerative Colitis Market, by Country, 2020-2030, ($Million)
Table 23. U.S. Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 24. U.S. Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 25. U.S. Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 26. Canada Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 27. Canada Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 28. Canada Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 29. Mexico Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 30. Mexico Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 31. Mexico Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 32. Europe Ulcerative Colitis Market, by Disease Type, 2020-2030, ($Million)
Table 33. Europe Ulcerative Colitis Market, by Molecule Type, 2020-2030, ($Million)
Table 34. Europe Ulcerative Colitis Market, by Route of Administration, 2020-2030, ($Million)
Table 35. Europe Ulcerative Colitis Market, by Country, 2020-2030, ($Million)
Table 36. Germany Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 37. Germany Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 38. Germany Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 39. France Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 40. France Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 41. France Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 42. U.K. Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 43. U.K. Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 44. U.K. Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 45. Italy Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 46. Italy Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 47. Italy Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 48. Spain Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 49. Spain Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 50. Spain Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 51. Rest of Europe Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 52. Rest of Europe Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 53. Rest of Europe Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 54. Asia-Pacific Ulcerative Colitis Market, by Disease Type, 2020-2030, ($Million)
Table 55. Asia-Pacific Ulcerative Colitis Market, by Molecule Type, 2020-2030, ($Million)
Table 56. Asia-Pacific Ulcerative Colitis Market, by Route of Administration, 2020-2030, ($Million)
Table 57. Asia-Pacific Ulcerative Colitis Market, by Country, 2020-2030, ($Million)
Table 58. Japan Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 59. Japan Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 60. Japan Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 61. China Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 62. China Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 63. China Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 64. India Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 65. India Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 66. India Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 67. Australia Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 68. Australia Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 69. Australia Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 70. South Korea Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 71. South Korea Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 72. South Korea Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 73. Rest of Asia-Pacific Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 74. Rest of Asia-Pacific Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 75. Rest of Asia-Pacific Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 76. LAMEA Ulcerative Colitis Market, by Disease Type, 2020-2030, ($Million)
Table 77. LAMEA Ulcerative Colitis Market, by Molecule Type, 2020-2030, ($Million)
Table 78. LAMEA Ulcerative Colitis Market, by Route of Administration, 2020-2030, ($Million)
Table 79. LAMEA Ulcerative Colitis Market, by Country, 2020-2030, ($Million)
Table 80. Brazil Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 81. Brazil Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 82. Brazil Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 83. Saudi Arabia Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 84. Saudi Arabia Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 85. Saudi Arabia Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 86. South Africa Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 87. South Africa Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 88. South Africa Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 89. Rest of LAMEA Ulcerative Colitis Market by Disease Type 2020-2030, ($Million)
Table 90. Rest of LAMEA Ulcerative Colitis Market by Molecule Type 2020-2030, ($Million)
Table 91. Rest of LAMEA Ulcerative Colitis Market by Route of Administration 2020-2030, ($Million)
Table 92. Abbott Laboratories: Company Snapshot
Table 93. Abbott Laboratories: Operating Segments
Table 94. Abbott Laboratories: Product Portfolio
Table 95. Abbott Laboratories: Net Sales
Table 96. Abbott Laboratories: Key Stratergies
Table 97. Ajinomoto Co. Inc.: Company Snapshot
Table 98. Ajinomoto Co. Inc.: Operating Segments
Table 99. Ajinomoto Co. Inc.: Product Portfolio
Table 100. Ajinomoto Co. Inc.: Net Sales
Table 101. Ajinomoto Co. Inc.: Key Stratergies
Table 102. Astrazeneca plc: Company Snapshot
Table 103. Astrazeneca plc: Operating Segments
Table 104. Astrazeneca plc: Product Portfolio
Table 105. Astrazeneca plc: Net Sales
Table 106. Astrazeneca plc: Key Stratergies
Table 107. Eli-Lilly: Company Snapshot
Table 108. Eli-Lilly: Operating Segments
Table 109. Eli-Lilly: Product Portfolio
Table 110. Eli-Lilly: Net Sales
Table 111. Eli-Lilly: Key Stratergies
Table 112. Index Pharmaceuticals Holdings Ab: Company Snapshot
Table 113. Index Pharmaceuticals Holdings Ab: Operating Segments
Table 114. Index Pharmaceuticals Holdings Ab: Product Portfolio
Table 115. Index Pharmaceuticals Holdings Ab: Net Sales
Table 116. Index Pharmaceuticals Holdings Ab: Key Stratergies
Table 117. Glaxosimithkline plc: Company Snapshot
Table 118. Glaxosimithkline plc: Operating Segments
Table 119. Glaxosimithkline plc: Product Portfolio
Table 120. Glaxosimithkline plc: Net Sales
Table 121. Glaxosimithkline plc: Key Stratergies
Table 122. Johnson & Johnson: Company Snapshot
Table 123. Johnson & Johnson: Operating Segments
Table 124. Johnson & Johnson: Product Portfolio
Table 125. Johnson & Johnson: Net Sales
Table 126. Johnson & Johnson: Key Stratergies
Table 127. Merck & Co. Inc.: Company Snapshot
Table 128. Merck & Co. Inc.: Operating Segments
Table 129. Merck & Co. Inc.: Product Portfolio
Table 130. Merck & Co. Inc.: Net Sales
Table 131. Merck & Co. Inc.: Key Stratergies
Table 132. Pfizer Inc.: Company Snapshot
Table 133. Pfizer Inc.: Operating Segments
Table 134. Pfizer Inc.: Product Portfolio
Table 135. Pfizer Inc.: Net Sales
Table 136. Pfizer Inc.: Key Stratergies
Table 137. Sanofi S.A: Company Snapshot
Table 138. Sanofi S.A: Operating Segments
Table 139. Sanofi S.A: Product Portfolio
Table 140. Sanofi S.A: Net Sales
Table 141. Sanofi S.A: Key Stratergies
LIST OF FIGURES
Figure 1. Ulcerative Colitis Market Segmentation
Figure 2. Ulcerative Colitis Market, 2020-2030
Figure 3. Ulcerative Colitis Market, 2020-2030
Figure 4. Top Investment Pockets, by Region
Figure 5. Porter Five-1
Figure 6. Porter Five-2
Figure 7. Porter Five-3
Figure 8. Porter Five-4
Figure 9. Porter Five-5
Figure 10. Top Player Positioning
Figure 11. Ulcerative Colitis Market:Drivers, Restraints and Opportunities
Figure 11. Ulcerative Colitis Market, by Disease Type, 2020 (%)
Figure 12. Comparative Share Analysis of Mild Uc Ulcerative Colitis Market, 2020-2030 (%)
Figure 13. Comparative Share Analysis of Moderate Uc Ulcerative Colitis Market, 2020-2030 (%)
Figure 14. Comparative Share Analysis of Severe Uc Ulcerative Colitis Market, 2020-2030 (%)
Figure 15. Ulcerative Colitis Market, by Molecule Type, 2020 (%)
Figure 16. Comparative Share Analysis of Biologics Ulcerative Colitis Market, 2020-2030 (%)
Figure 17. Comparative Share Analysis of Small Molecules Ulcerative Colitis Market, 2020-2030 (%)
Figure 18. Ulcerative Colitis Market, by Route of Administration, 2020 (%)
Figure 19. Comparative Share Analysis of Oral Ulcerative Colitis Market, 2020-2030 (%)
Figure 20. Comparative Share Analysis of Injectables Ulcerative Colitis Market, 2020-2030 (%)
Figure 21. Ulcerative Colitis Market by Region, 2020
Figure 22. U.S. Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 23. Canada Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 24. Mexico Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 25. Germany Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 26. France Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 27. U.K. Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 28. Italy Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 29. Spain Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 30. Rest of Europe Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 31. Japan Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 32. China Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 33. India Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 34. Australia Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 35. South Korea Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 36. Rest of Asia-Pacific Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 37. Brazil Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 38. Saudi Arabia Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 39. South Africa Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 40. Rest of LAMEA Ulcerative Colitis Market, 2020-2030 ($Million)
Figure 41. Top Winning Strategies, by Year
Figure 42. Top Winning Strategies, by Development
Figure 43. Top Winning Strategies, by Company
Figure 44. Product Mapping of Top 10 Players
Figure 45. Competitive Dashboard
Figure 46. Competitive Heatmap of Top 10 Key Players
Figure 47. Abbott Laboratories.: Net Sales, ($Million)
Figure 48. Ajinomoto Co. Inc. Net Sales, ($Million)
Figure 49. Astrazeneca PLC.: Net Sales, ($Million)
Figure 50. Eli-Lilly.: Net Sales, ($Million)
Figure 51. Index Pharmaceuticals Holdings Ab.: Net Sales, ($Million)
Figure 52. Glaxosimithkline PLC.: Net Sales, ($Million)
Figure 53. Johnson & Johnson.: Net Sales, ($Million)
Figure 54. Merck & Co. Inc. Net Sales, ($Million)
Figure 55. Pfizer Inc. Net Sales, ($Million)
Figure 56. Sanofi SA: Net Sales, ($Million)

Executive Summary

According to this report titled, 'Ulcerative Colitis Market,' the ulcerative colitis market was valued at $6.2 billion in 2020, and is estimated to reach $10.8 billion by 2030, growing at a CAGR of 5.7% from 2021 to 2030.
Ulcerative colitis is an inflammatory bowel disease that affects the colon and rectum of the human body. The disease affects people of any age and most commonly it begins during adolescence and early adulthood, but it may also occur later in life. Ulcerative colitis is highly prevalent in the U.S., England, and northern Europe. The most commonly preferred treatment options for ulcerative colitis are traditional medications made of biologics and small molecules.

Factor that drives the ulcerative colitis market growth include increase in number of inflammatory bowel disease. In addition, rise in number of ulcerative colitis incidences propels growth of the market. However, rise in burden of inflammatory bowel disease increases growth of the market. Furthermore, the Food and Drug Administration (FDA) aims to enhance availability of reliable and effective drugs to meet public health needs and increase access to treat consumers.

Moreover, rise in development of pharmaceutical and medical device industries and improvement in healthcare spending are anticipated to drive growth of the ulcerative colitis market. In addition, increase in development of new product launches led to rise in the healthcare sector, thereby propelling growth of the market.

Moreover, governments initiatives for development of new drugs and healthcare sector for manufacturing of ulcerative colitis drugs are the key factors that boost growth of the market.

For instance, in May 2018, Takeda Pharmaceutical Company Ltd. and Shire Plc. announced that Takeda had reached an agreement on the terms of proposed offer to acquire all of outstanding shares and future common shares of Shire Plc. In addition, in June 2019, Abbvie completed the acquisition of Allergan to expand its product portfolio to offer extensively advanced treatments for patients. Allergan launched a monoclonal antibody called brazikumab, which is used in the treatment of ulcerative colitis. Thus, increase in development of new drugs drives the substantial growth of the ulcerative colitis market size during forecast period.

The global ulcerative colitis market is segmented on the basis of disease type, molecule type, route of administration, and region. On the basis of disease type, the market is fragmented into mild ulcerative colitis, moderate ulcerative colitis, and severe ulcerative colitis. The mild UC segment dominated the market in 2020, and this ulcerative colitis market trends is expected to continue during the forecast period, owing to increase in number of inflammatory bowel disease cases, advancements in R&D activities in pharmaceutical industries, and surge in adoption of ulcerative colitis drugs.

By molecule type, the market is divided into small molecules and biologics. The small molecule segment acquired top position in the ulcerative colitis industry in 2020, and this trend is expected to continue during the forecast period, owing to large number of drugs offered by key players and increase in use of drugs for the treatment of inflammatory gastrointestinal disorder. By route of administration, the market is fragmented into oral and injectables.
Region wise, North America accounted for a majority of the global ulcerative colitis market share in 2020, and is anticipated to remain dominant during the forecast period. This is attributed to rise in prevalence of inflammatory bowel disease, increase in number of approvals for ulcerative colitis drugs, presence of key players, and advancement in the development of drugs in the region. Asia-Pacific is anticipated to witness lucrative growth, owing to increase in deficiency of vitamin D in the countries, rise in number of geriatric populations, growth in health care expenditures, and rise in adoption of effective drugs.

Key findings of the Study

  • By disease type, the mild UC segment was the highest contributor to the market in 2020.
  • On the basis of molecule type, the small molecule segment dominated the market in 2020, and is expected to continue this trend during the forecast period.
  • On the basis of route of administration, the oral segment dominated the market in 2020, and is expected to continue this trend during the forecast period
  • Region wise, North America garnered the largest revenue share in 2020, whereas Asia-Pacific is anticipated to grow at the highest CAGR during the forecast period.

Companies Mentioned

  • ABBOTT LABORATORIES
  • AJINOMOTO CO. INC.
  • ASTRAZENECA PLC
  • ELI-LILLY
  • INDEX PHARMACEUTICALS HOLDINGS AB
  • GLAXOSIMITHKLINE PLC
  • JOHNSON & JOHNSON
  • Merck & Co. Inc.
  • Pfizer Inc.
  • SANOFI S.A

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages225
PublishedMarch 2022
Forecast Period2020 - 2030
Estimated Market Value ( USD ) in 2020 $ 6180.29 million
Forecasted Market Value ( USD ) by 2030 $ 10764.66 million
Compound Annual Growth Rate5.7%
Regions CoveredGlobal
No. of Companies Mentioned10

Related Topics

Related Reports

Global Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Forecast 2024-2030 - Product Image

Global Ulcerative Colitis Market by Drug (Anti-Inflammatory Drugs, Anti-TNF Biologics, Calcineurin Inhibitors), Disease (Fulminant Colitis, Left-Sided Colitis, Pancolitis or Universal Colitis), Route of Administration - Forecast 2024-2030

  • Report
  • 189 Pages
  • Global
From
Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028 - Product Image

Ulcerative Colitis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

  • Report
  • 146 Pages
  • Global
From
Global Ulcerative Colitis Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 - Product Image

Global Ulcerative Colitis Market - Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028

  • Report
  • 190 Pages
  • Global
From
Global Ulcerative Colitis Market - Product Image

Global Ulcerative Colitis Market

  • Report
  • 200 Pages
  • Global
From
Ulcerative Colitis Therapeutics - Global Strategic Business Report - Product Image

Ulcerative Colitis Therapeutics - Global Strategic Business Report

  • Report
  • 181 Pages
  • Global
From
Copyright © 2002-2024 Research and Markets. All Rights Reserved.